Eosinophilic Esophagitis Disease Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Product Type (Off-Label Drugs, Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab), By Channel (Hospitals, Clinics), And By Geography - Forecasts From 2022 To 2027
- Published : Nov 2022
- Report Code : KSI061612287
- Pages : 125
The Eosinophilic esophagitis disease treatment market is projected to grow at a CAGR of 8.43% during the forecast period to reach US$569.591 million by 2027, from US$323.154 million in 2020.
EoE (Eosinophilic esophagitis) is a disease of the chronic type. Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis share symptoms such as chest pain and difficulty swallowing. It was considered a common disease in children for many years but has now grown in cases in young people that can be registered. Common symptoms of EOE are difficulty swallowing, pain in the chest cavity and upper abdomen, and vomiting.
The condition of eosinophilic Esophagitis occurs when the oesophagus is filled with white blood cells, which are also known as eosinophils. These eosinophils should remain inside the digestive tract if they build up elsewhere, creating discomfort and inflammation inside the organ.
The market for eosinophilic esophagitis disease treatment is expected to be pushed by the rising prevalence of type II inflammatory illnesses, such as EoE, advancements in treatment approaches, and fierce competition among competitors for the first FDA-approved medicine to gain a first-mover advantage. EoE has a lot of needs, which is helping the eosinophilic esophagitis medication sector flourish. EoE diagnosis criteria are flawed since they are reliant on professional opinions (agreement among gastroenterologists, allergists, and pathologists) rather than evidence. Because there is no correlation between disease activity and patient symptoms, histologic criteria for EoE are currently unclear, and repeated tissue testing is required to confirm disease initiation.
The following are the symptoms of Eosinophilic Esophagitis in adults and children: In adults, symptoms are the backflow of undigested food, chest pain while chewing food that gets stuck in the esophagus, and difficulty in chewing and swallowing the food. In a child, some symptoms are common, like difficulty swallowing, and food getting stuck in the esophagus, while other symptoms in the child are vomiting, abdominal pain, difficulty eating, and no response to the medication.
Over the projection period, the worldwide eosinophilic esophagitis market is expected to develop due to increased awareness campaigns for eosinophil-associated illnesses.
Various public and medical awareness programs have been designed and implemented to educate the public and medical community about eosinophil-related illnesses, which is expected to fuel market expansion.
The market for eosinophilic esophagitis is being driven by an increase in the occurrences of digestive tract inflammatory illnesses. Eosinophilic esophagitis (EoE) market growth is expected to be boosted by increased allergies in the esophagus, eosinophil build-up, dysphagia, and impaction in the esophagus.
The global eosinophilic esophagitis (EoE) market may be hampered by a lack of disease awareness and acceptability of treatment for a given location. For the time being, no specific treatment for eosinophilic esophagitis has been approved. There are numerous hurdles connected with acquiring regulatory permission, which is expected to hamper market expansion over the projection period. Obtaining regulatory approval for the drug is time-consuming and difficult, as regulatory agencies such as the US Food and Drug Administration (FDA) place significant and stringent restrictions on organizations involved in the clinical development, manufacture, marketing, and distribution of drugs.
North America expected to dominate the Eosinophilic Esophagitis Treatment Market.
With the rising demand for asthma risk-reducing medications and high-end medical treatments, it is predicted that North America will have the biggest market volume in the Eosinophilic Esophagitis Treatment Market.
Because of the increased occurrence of allergies that cause eosinophilic illnesses, Europe is expected to be the second-largest market for eosinophilic esophagitis (EoE). Due to growing awareness and the existence of generic companies, Asia-Pacific is likely to account for the biggest market share in the eosinophilic esophagitis (EoE) market in the forecasted period.
However, in places such as the Middle East, Africa, and South America, high therapeutic costs and a lack of patient information are limiting the eosinophilic esophagitis market.
- In May 2022, Sanofi, an innovative global healthcare company announced that Dupixent® (Dupilumab) has been approved by FDA. Dupixent is approved as the first treatment for adults and children aged 12 and older with eosinophilic esophagitis claims the company. Further, the company claims that it is the first and only medicine indicated to treat eosinophilic esophagitis in the US.
- AstraZeneca announced that the FDA granted Orphan Drug Designation to Fasenra (benralizumab) in August 2019 for the treatment of eosinophilic oesophagitis (EoE). Fasenra is a monoclonal antibody that is a first respiratory biological medicine of AstraZeneca.
The pandemic had a significant impact on the EoE disease treatment market. The viral outbreak in numerous countries has generated certain challenges in providing Eosinophilic Esophagitis disease therapy, which was provided in hospitals and clinics as the healthcare industry was overburdened with COVID cases. The immense demand for hospitals to provide care to COVID-19 patients is one of the issues prohibiting clinics and hospitals from providing therapy for Eosinophilic Esophagitis.
Eosinophilic Esophagitis Disease Treatment Market Scope:
|Market size value in 2020||US$323.154 million|
|Market size value in 2027||US$569.591 million|
|Growth Rate||CAGR of 8.43% from 2020 to 2027|
|Forecast Unit (Value)||USD Million|
|Segments covered||Product Type, Channel, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Baker Hughes Incorporated, Halliburton Company, Schlumberger Ltd., E.I. du Pont de Nemours and Company, Pioneer Engineering Services, BASF SE|
|Customization scope||Free report customization with purchase|
- By Product Type
- Off-Label Drugs
- Budesonide Oral Suspension
- Fluticasone ODT
- By Channel
- By Geography
- North America
- South America
- United Kingdom
- The Middle East and Africa
- Saudi Arabia
- Asia Pacific
- South Korea
- North America
Frequently Asked Questions (FAQs)
Q1. What is the size of the global eosinophilic esophagitis disease treatment market?
A1. Eosinophilic Esophagitis Disease Treatment Market was valued at US$323.154 million in the year 2020.
Q2. What will be the eosinophilic esophagitis disease treatment market size by 2027?
A2. The eosinophilic esophagitis disease treatment market is projected to reach a market size of US$569.591 million by 2027.
Q3. What are the growth prospects for the eosinophilic esophagitis disease treatment market?
A3. The global eosinophilic esophagitis disease treatment market is projected to grow at a CAGR of 8.43% during the forecast period.
Q4. What factors are anticipated to drive the eosinophilic esophagitis disease treatment market growth?
A4. The global eosinophilic esophagitis market is expected to grow due to increased awareness campaigns for eosinophil-associated illnesses.
Q5. Which region holds the maximum market share in the eosinophilic esophagitis disease treatment market?
A5. North America is expected to hold the largest share in the eosinophilic esophagitis disease treatment market due to the rising demand for asthma risk-reducing medications and high-end medical treatments.
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. ESOINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY PRODUCT TYPE
5.2. Off-Label Drugs
5.3. Budesonide Oral Suspension
5.4. Fluticasone ODT
6. ESOINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY CHANNEL
7. ESOINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET, BY GEOGRAPHY
7.2. North America
7.2.1. United States
7.3. South America
7.4.3. United Kingdom
7.5. The Middle East and Africa
7.5.1. Saudi Arabia
7.6. Asia Pacific
7.6.4. South Korea
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrative
8.3. Mergers, Acquisition, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. Ellodi Pharmaceuticals
9.2. AstraZeneca Plc
9.3. Bristol-Myers Squibb Co
9.4. GlaxoSmithKline Plc
9.6. Takeda Pharmaceutical Company Limited.
Bristol-Myers Squibb Co
Takeda Pharmaceutical Company Limited
|Report Name||Published Month||Get Sample PDF|
|Idiopathic Pulmonary Fibrosis Treatment Market Size: 2022-2027||Mar 2022|
|Merkel Cell Carcinoma Disease Treatment Market Size: 2022-2027||Mar 2022|
|Gaucher Disease Treatment Market Size & Share: Report, 2022-2027||Apr 2022|
|IgA Nephropathy Disease Treatment Market Size: 2022-2027||Mar 2022|